Under the agreement, Catalent and CTC Bio will align their expertise and experience in innovative drug delivery technologies to enableSouth Korean pharmaceutical companies access to global markets for their products and formulations.
Combining CTC Bio's leading position in the region with Catalent's expertise in controlled release formulations, manufacturing network and broad experience in global product launches will provide South Korean companies with unparalleled access to international markets.
“South Korea is a highly innovative region, developing new products and effective pharmaceutical formulations,” said Dr. HR Jeon, Chief Science Officer of CTC Bio. This collaboration with Catalent provides South Korean pharmaceutical customers with better access to the leading provider of innovative controlled release drug delivery technologies and supply capabilities. Catalent's breadth of services and reputation for successful new product launches in international markets makes them an ideal partner for us and our clients/partners in South Korea.”
Ian Muir, President of Catalent's Modified Release Technologies business, commented “CTC Bio is a leading regional provider of innovative drug products and formulation services and its capabilities perfectly complement those of Catalent. In collaboration with CTC Bio, Catalent can now provide South Korean pharmaceutical customers with seamless scale-up and transfer within Catalent's controlled release capabilities at our Winchester, KY and Somerset, NJ facilities in the U.S. and at Schorndorf, Germany in Europe. These are leading commercial facilities for oral solids and controlled release dosage forms, ensuring that commercial manufacture for global supply is carried within the target markets and meets all international standards of quality and reliability.”
Companies in this article
